Evenamide, a Glutamate Release Modulator, as Add-On to Standard of Care in Subjects With Documented Treatment-Resistant Schizophrenia
Public ClinicalTrials.gov record NCT07184619. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Phase III, 12-week, Prospective, Randomized, Double-blind, Placebo-controlled, Parallel-group, Multi-center Study to Determine the Efficacy, Safety, and Tolerability of a Dose of 15 mg Bid of Evenamide as add-on in Patients With Documented Treatment-resistant Schizophrenia, Which is Not Adequately Controlled by a Stable Therapeutic Dose of the Patient's Current Antipsychotic Medication(s)
Study identification
- NCT ID
- NCT07184619
- Recruitment status
- Recruiting
- Study type
- Interventional
- Phase
- Phase 3
- Lead sponsor
- Newron Pharmaceuticals SPA
- Industry
- Enrollment
- 400 participants
Conditions and interventions
Conditions
Interventions
- Evenamide 15 mg bid Drug
- Placebo Drug
Drug
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Jan 22, 2026
- Primary completion
- Aug 31, 2026
- Completion
- Aug 31, 2026
- Last update posted
- Apr 2, 2026
2026
United States locations
- U.S. sites
- 5
- U.S. states
- 5
- U.S. cities
- 5
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| UCLA DGSOM, UCLA Health, UCLA Semel Institute | Los Angeles | California | 90095 | Recruiting |
| University of Miami, Miller School of Medicine; Jackson Behavioral Health Hospital | Miami | Florida | 33136 | Not yet recruiting |
| Grady Behavioral Health Center, -Department of Psychiatry and Behavioral Sciences, Emory University School of Medicine | Atlanta | Georgia | 30322 | Not yet recruiting |
| Department of Psychiatry and Behavioral Sciences, Johns Hopkins University School of Medicine | Baltimore | Maryland | 21224 | Recruiting |
| Manhattan Psychiatric Center, The Nathan Kline Institute for Psychiatric Research | New York | New York | 10035 | Recruiting |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT07184619, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Apr 2, 2026 · Synced May 17, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT07184619 live on ClinicalTrials.gov.